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Abstract
Persistent high-risk human papillomavirus (HR-HPV) is a necessary and causal factor of cervical cancer. Most women
naturally clear HPV infections; however, the biological mechanisms related to HPV pathogenesis have not been clearly
elucidated. Host genetic factors that specifically regulate immune response could play an important role. All HIV-positive
women in the HIV Epidemiology Research Study (HERS) with a HR-HPV infection and at least one follow-up biannual visit
were included in the study. Cervicovaginal lavage samples were tested for HPV using type-specific HPV hybridization assays.
Type-specific HPV clearance was defined as two consecutive HPV-negative tests after a positive test. DNA from participants
was genotyped for 196,524 variants within 186 known immune related loci using the custom ImmunoChip microarray. To
assess the influence of each single-nucleotide polymorphism (SNP) with HR-HPV clearance, the Cox proportional hazards
model with the Wei-Lin-Weissfeld approach was used, adjusting for CD4+ count, low risk HPV (LR-HPV) co-infection, and
relevant confounders. Three analytical models were performed: race-specific (African Americans (n = 258), European
Americans (n = 87), Hispanics (n = 55), race-adjusted combined analysis, and meta-analysis of pooled independent race-
specific analyses. Women were followed for a median time of 1,617 days. Overall, three SNPs (rs1112085, rs11102637, and
rs12030900) in the MAGI-3 gene and one SNP (rs8031627) in the SMAD3 gene were associated with HR-HPV clearance (p,
1026). A variant (rs1633038) in HLA-G were also significantly associated in African American. Results from this study support
associations of immune-related genes, having potential biological mechanism, with differential cervical HR-HPV infection
outcomes.
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Introduction
HPV DNA is present in 99.7% of all cervical cancer, the third
most common cancer in women worldwide, with HPV types 16,
18, 31 and 45 being the most predominant HR-HPV types [1–5].
HPV is a common sexually transmitted infection and the majority
of those infected are able to clear the infection naturally and only a
small proportion will progress to cervical cancer [6,7]. A persistent
infection of a HR-HPV type is considered the most important
factor for development of pre-cancer high-grade lesions and
progression to cervical cancer [8]; although, it is not a sufficient
cause. Further, while cervical cancer is a definitive end to the
stages of progression associated with HPV infection, it is important
to understand the earlier biological processes of HPV persistence
in the host.
The factors that lead to the development of a persistent HPV
infection in some women, but not others, remain unclear. The role
of host genetics that regulate biological mechanisms of immune
response may contribute to the differential responses to infection
and HPV clearance among women. To our knowledge, most
research on host genetics including genome-wide association
studies (GWAS) have focused on cervical cancer as the outcome
[9,10], and few have investigated the influence on HPV
persistence, the intermediate phenotype to cervical cancer. Even
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with the limited genetic epidemiology studies of HPV infection as
an outcome, the study designs have been predominantly cross-
sectional, comparing genetic variants between women with HPV-
positive cervical cancer and randomly selected controls [11,12].
Since persistence of HPV is time-dependent, longitudinal studies
assessing HPV over time would be more appropriate to examine
the true association. Several studies implicate immune evasion
[13–15] involving genetically mediated determinants of the
localized cell-mediated immune response in the host to be an
important factor in the pathogenesis of HPV infection [16,17].
Specifically, human leukocyte antigens (HLA) variants (DRB1*13
and DRB1*1501-DQB1*06) have been shown to be associated with
cervical cancer [10,18] and possibly HPV infection [19]. Further,
even among women who naturally clear HPV infection, there are
differences in time to clearance suggesting the role of the host
immune system. While HPV persistence is necessary for develop-
ment of most cervical premalignant and cancers, the role of
immune-related genes (such as those in the ImmunoChip) are
biologically meaningful in relation to viral pathogenesis and may
or may not be involved in the development or progression of pre-
cancer lesions. The knowledge of immune response will comple-
ment our understanding of the pathogenesis of HPV. Our
objective was to assess the association of host genetic variants in
immune-related genes with clearance of HR-HPV using the
Human ImmunoChip in HIV-positive African Americans, His-
panics, and European women.
Materials and Methods
Ethics Statement
Written consent was obtained from all participants (parental
written permission was obtained for minorities wherever required)
and the study protocols for the parent study and this sub-study was
approved by institutional review boards (IRB) at all sponsoring
organizations and conformed to human-experimentation guide-
lines set forth by the United States Department of Health and
Human Services. All protocols including the genetic work was
finally reviewed and approved by the University of Alabama at
Birmingham IRB.
Study Population
Participants from the HIV Epidemiology Research Study
(HERS) cohort were included in this study [20,21]. HERS is a
multicenter, prospective study established by the Centers for
Disease Control and Prevention (CDC) to examine the natural
history of HIV in women. Women aged 16–55 with documented
HIV status and high-risk behaviors were recruited between April
1993 and January 1995. The exclusion criteria in the parent study
were as follows: i) had no identified HIV risk behavior; ii) had risk
only by transfusion history or vertically from HIV-positive mother;
iii) were not born female (i.e., transsexual); iv) did not consent to
the full protocol, including pelvic exam, phlebotomy, and repeated
HIV testing and counseling; and v) reported previously having
AIDS-defining illnesses. Of the 1,994 women screened, 1,310
(66%) were enrolled in the study (871 HIV-positive and 439 HIV-
negative). After enrollment, the core visit included a physical
examination with complete gynecologic exam and specimen
collection. Blood was tested for CD4+ T lymphocyte cells
(CD4+) count and HIV viral load at 6-month intervals.
HPV DNA Detection and Classification
HPV testing was performed on all HERS women at enrollment
and every 6 months thereafter using cervicovaginal lavage
samples. Viral DNA fragments from cervicovaginal lavage were
amplified by using the consensus primers MY09/11 and HMB01
and were hybridized for a consensus probe and for 26 HPV types
HR-HPV: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68,
73, and 82 and LR-HPV: 6, 11, 40, 42, 53, 54, 55, 83, and 84
using a chemiluminescent dot-blot format [20]. PCR-based HPV
data were classified as a) negative, b) positive for the specific types,
or c) positive, type unknown if the sample was positive for the
generic probe but not for a specific HPV type. PCR amplification
of a human b-globin gene segment was used as an internal control
for DNA quality; samples negative for this assay were excluded
from analyses.
The analysis was performed in HIV-positive women in HERS
who had no cervical treatment and were not pregnant during the
follow-up. HIV-positive women with prevalent or incident HR-
HPV infection who had peripheral blood mononuclear cells
(PBMC) available at the baseline visit and at least one follow-up
visit were included in the genetic analysis. In this study, the
analyses focused on clearance of HR-HPV infections since these
types are most likely to be associated with risk of pre-cancer and
cancer of cervix and the models were adjusted for LR-HPV
infections in order to account for the correlation between HPV
subtypes. For the analysis, type-specific HPV status was assumed
to remain unchanged across single missing visits. For women who
tested negative for HPV at their last study visit, results were
censored at that visit. Type-specific HPV clearance was defined as
two consecutive HPV-negative tests to avoid the possibility of false-
negative test results.
Genotyping
Genomic DNA was extracted from stored PBMC and
genotyped using the Human ImmunoChip, an iSelect HD custom
genotyping array (Illumina, Inc.). The ImmunoChip is a custom
SNP microarray developed by a consortium of specialists in the
fields of immunology and inflammation. The microarray chip
contains densely spaced 196,524 SNP variants (5,001 non-
synonymous coding, 1,926 synonymous coding, and 4,065 in the
untranslated region (UTR)), previously reported from GWAS and
candidate gene studies of major autoimmune and inflammatory
diseases [22,23]. The genotyping of the samples was processed at
two different laboratory facilities, and this was adjusted for in the
statistical models.
Immunochip Genotype Calling and Quality Control
Data were analyzed using the Genome Studio Genotyping
Module (Illumina, Inc.). The National Center for Biotechnology
Information (NCBI) build 36 (hg18) map was used and the
normalized probe intensities were extracted for all samples that
passed standard laboratory quality-control (QC) thresholds. The
Immunochip contains 763 duplicate SNPs and these were checked
for concordance. Additionally, 174 genotyping assays failed which
left 195,587 SNPs. All SNPs were checked for completeness (by
SNP and by subject), rare variants, and deviation from Hardy-
Weinberg Equilibrium (HWE) within each ethnic group separate-
ly. First, a large proportion of SNP assays failing on an individual
may indicate poor quality of DNA sample and thus to avoid
aberrant genotype calling, the threshold was set to 90% coverage.
All African Americans and European Americans samples met this
criterion, but 2 Hispanic samples did not and thus were removed
from the analyses. Second, missing genotype data from a large
number of individuals indicate poor assay quality for that SNP,
and there were 5171 SNPs in African Americans, 5889 SNPS in
European Americans and 6131 SNPs in Hispanics that were
missing in more than 10% of individuals and were removed from
the analysis. Third, there were 71,488 SNPs in African Americans,
Immunogenetics of HPV Clearance
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73,017 in European Americans, and 68,264 in Hispanics that had
a minor allele frequency less than 5% (rare variants) that were also
removed in the analysis of each ethnic group, respectively. Fourth,
there were 1234 SNPs in African Americans, 442 SNPs in
European Americans, and 347 SNPs in Hispanics that deviated
from HWE (p-value,0.001), and thus were also removed from the
analyses. Further, kinship between the individuals was also
assessed in KING software [24], and two of the African American
individuals were determined to be genetically related. However,
one of the individuals had a lot of missing data and the relatedness
seems likely due to specimen contamination; this individual was
removed from the analyses (removal of both individuals did not
change the results of the analysis). There were no major differences
with the genotype call rates, minor allele frequency between the
two genotyping facilities; however, they were adjusted for in all our
analyses. After applying the QC methods above, there were 258
African Americans with 117,694 SNPs, 87 European Americans
with 116,239 SNPs, and 55 Hispanics with 120,845 SNPs included
in the analysis.
The same QC methods mentioned above for each ethnic group
separately were then applied to the combined analysis which
contained all three ethnic groups. For the combined analysis of all
three distinct race (described below), there were 5190 SNPs
removed because of low genotyping calls and an additional 66,536
rare variants (,0.05%) across any one ethnic group and were
removed; thus, 123,861 SNPs were available for analysis. Since
SNPs in the ImmunoChip are mostly in the fine-mapped regions
with high linkage disequilibrium (LD), correction for multiple
testing was performed based on the effective number of tests which
resulted after pairwise correlations between markers, as previously
described [25]. Based on this matrix, there were 94,307 effective
tests among African Americans, 93,164 among European Amer-
icans, and 96,967 among Hispanics that resulted in adjusted p-
value corrections of 5.3061027, 5.3761027, and 5.1661027,
respectively. Additionally, among the SNPs common in all three
ethnic groups, there were 80,510 effective numbers of tests
(adjusted p value = and 6.2161027).
Statistical Analysis
Cox proportional hazard models with the Wei-Lin-Weisfeld
(WLW) extension [26] were used to assess the influence of all SNPs
(individually) with clearance of HR-HPV [27]. This approach can
simultaneously analyze time to HPV clearance of several types of
HPV either at the same or different visits, taking into account
possible correlation between the types and also has population-
level interpretation [8,26], making it appropriate for epidemio-
logical studies. The WLW model was implemented in SAS using
PHREG procedure, selecting the STRATA option to allow
different baseline hazards function for each HPV type and robust
variance.
To test for potential confounding effects of population
stratification in our study cohort, principal component (PC)
analysis was performed. Self-reported race (African Americans,
European Americans, and Hispanics) was confirmed using
clustering as implemented in EIGENSTRAT, and all individuals
were confirmed with no apparent population outliers [28]. Hazard
ratios (HR) and 95% confidence intervals were calculated for all
races (n = 400) combined into one model (referred to as ‘‘race-
adjusted analysis’’) adjusting for the first 10 PC values. Hazard
ratios (HR) and 95% confidence intervals were also calculated for
each race separately (African Americans (n = 258), European
Americans (n = 87), and Hispanics (n = 55)) adjusting for the first
three PC values. Further, a meta-analysis was using PLINK [29]
pooling the results from individual race-specific analyses (referred
to as ‘‘pooled analysis’’).
All SNP analyses were conducted using an additive genetic
model, adjusting for CD4+ count, which served as a marker for
immune status as well as a surrogate for HIV treatment. CD4+
count was adjusted for in the model at all visits when an individual
was infected with HPV, which allowed CD4+ count to serve as a
time-varying covariate. LR-HPV infections were adjusted for in
the model when an individual was co-infected with any HR-HPV
type, which also allowed LR-HPV to serve as a time-varying
covariate when infection time overlapped. Quantile-quantile (Q-
Q) plots of p-values were constructed to evaluate deviations from
the expected test statistic distribution. ImmunoChip based
Manhattan plots were generated to visualize the results.
Results
The average age at baseline of the 400 HIV-positive women
included in the study was 34 years and their median baseline
CD4+ count was 426.3 cells/mm3 [interquartile range (IQR):
262.3–546.1 cells/mm3]. Women were followed for a median time
of 1,617 days (range 324–1729 days). Among the 400 women,
there were 1052 HR-HPV infections, and 668 (64%) cleared
during follow up. The most common HR-HPV types were HPV18
(n= 99), HPV16 (n= 88), HPV51 (n= 88), HPV58 (n= 83), and
HPV52 (n = 79). Of the 668 infections that cleared during follow
up, the average time to clearance was 457.9 days (median 322
days). Among the HR-HPV infections that cleared during follow-
up, the average CD4+ count was 385.1 cells/mm3 (median 336.7
cells/mm3). Among the HR-HPV infections that persisted during
follow-up, the average CD4+ count was 251.1 cells/mm3 (median
212.9 cells/mm3).
The Manhattan plots (Figures 1A–D) summarize the results
from the association between HR-HPV clearance and the SNPs in
the ImmunoChip (Q-Q plots - Figures S1A–D). All significant hits
based on the K-effective method described above are presented for
the three analytical models in Table 1 (race-adjusted analysis,
race-specific analysis, and the pooled analysis). Results for all of the
SNPs assessed can be found in Table S1. In the race-adjusted
analysis, three SNPs that are in LD (rs1112085, rs11102637, and
rs12030900) in the MAGI3 gene were associated with HPV
clearance. HIV-positive women infected with HR-HPV that have
minor allele A for SNP rs1112085, located on chromosome 1, had
a HPV clearance rate 1.51 times (p = 1.14610207) higher than
those with the G wild type allele, controlling for CD4+ count, LR-
HPV infection(s), 10 PCs, and genotyping facility (Table 1). When
assessing this SNP (rs1112085) in the three races separately
(Table 1), in African Americans and European Americans the
minor allele was associated with higher clearance rates
(HR=1.49, p= 4.07610205, HR=1.53, p = 0.01, respectively),
while no association was detected between this SNP and HR-HPV
clearance among Hispanics (HR=0.98, p = 0.91). In the pooled
analysis using the meta-analysis approach, the same minor allele
was associated with higher clearance rates (HR=1.33, p = 0.03).
Likewise, a SNP (rs8031627), located on chromosome 15 in the
SMAD3 gene, was also significantly associated with higher
clearance rates in the race-adjusted analysis (HR=1.53,
p = 8.04610207) and the pooled analysis (HR=1.49,
p = 1.78610206). When analyzed among the separate races, the
SNP (rs8031627) was significantly associated with clearance in
Hispanics (HR=1.76, p = 0.0005) and African Americans
(HR=1.44, p = 0.003); a similar hazard ratio was seen in
European Americans, but it was not statistically significant
(HR=1.34, p = 0.08).
Immunogenetics of HPV Clearance
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A SNP (rs1633038) located on chromosome 6 in the HLA-G
gene region, was significantly associated with higher clearance
rates (HR=1.89, p= 3.48610207) in African Americans, although
this was not observed in Hispanics or European Americans
separately. Several other SNPs presented in Table 1 were
significantly associated with clearance; however, to date, biological
relevance of these SNPs and HPV is unclear.
Discussion
We report several variants in immune related genes that are
associated with clearance of HR-HPV infection in African
Americans, Hispanics, and European Americans HIV-positive
women after accounting for the effects of CD4+ count, other LR-
HPV co-infection(s), population stratification, and genotyping
facility. In particular, CD4+ has been a major factor with HPV
persistence/clearance among HIV patients; thus it was adjusted as
a time-varying covariate. Also, none of the top hits in table 1 was
associated with CD4+ change over time of infection, suggesting
that these are independent SNP associations. The most significant
association with time to clearance of HR-HPV in the adjusted
analysis was seen with several SNPs located on chromosome 1
within the MAGI3 gene region: rs1112085, rs11102637, and
rs12030900 (in LD). The minor alleles for these SNPs in LD were
associated with faster time (days) to clearance. MAGI-3 is part of
the membrane-associated guanylate kinases (MAGUK) family of
proteins that have inverted domain structure, and are part of the
PDZ domain-containing proteins, which are localized between
epithelial cells [30,31]. The E6 protein of HPV inhibits cellular
apoptosis or growth arrest [32]. Several in vivo studies have shown
that HR-HPV E6 proteins target MAGI-1,-2,-3 proteins for
degradation [30,31,33]. This degradation process appears to be
necessary for cell transformation [31,34]. Women in our cohort
that had the minor allele for the SNPs in the intragenic region of
MAGI-3 cleared the HPV infection faster than those with the
major allele, and we hypothesize that these genetic variants may
interact with HPV differently and therefore affect time to
clearance.
Another interesting finding was that the minor allele for SNP
rs8031627 located on chromosome 15 in the SMAD3 gene was
significantly associated with higher clearance rates in the adjusted
analysis. SMAD proteins are signal transducers and transcriptional
modulators that mediate multiple signaling pathways including
TGF-b signals [35,36], which inhibits the proliferation of most
epithelial cells [36]. The E7 protein of HPV has been shown in vivo
to block SMAD3 by binding to its target sequence of DNA, which
then also inhibits TFG-b for inhibiting DNA synthesis [36]. Again,
Figure 1. Manhattan plot showing the association P-values of single nucleotide polymorphisms (SNPs) in the ImmunoChip with the
time to clearance of HR-HPV. The X-axes display the chromosome on which the SNP is located, the Y-axes display 2log10 P-value. The dashed
black line represents a significance level needed for multiple testing using the K effective method. Panel A.) Race-adjusted analysis B.) African
Americans only C.) European Americans only, and D.) Hispanics only.
doi:10.1371/journal.pone.0099109.g001
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women in our cohort that had the minor allele for the SNP in
UTR of SMAD3 cleared the HPV infection faster than those with
the major allele. We hypothesize that the major allele variant may
interact with HPV differently and therefore increase time to
clearance.
Interestingly, the most significant association with time to
clearance of HR-HPV in the African Americans analysis was with
the SNP rs1633038 located on chromosome 6. The minor allele
for SNP rs1633038 was associated with faster time (days) to
clearance 1.9 times (HR=1.89, p = 3.4861027) in that those that
were homozygous for the minor allele had faster clearance
compared to heterozygous and homozygous for the major allele.
This SNP is located in chromosome 6 near the HLA-G gene
region. HLA-G is a nonclassical HLA class Ib molecule that
regulates the immune response through interaction with surface
receptors on natural killer, T and antigen-presenting cells [37–40].
Several studies have reported associations between HLA-G
polymorphisms and HPV infection susceptibility and persistence
[39–41]. A 14 base pair deletion in the 39 of HLA has also been
shown to promote high-risk HPV infection and invasive cervical
cancer in various populations [42–44]. In our study we report an
association between a SNP near the HLA-G region and HPV
clearance; however, specific HLA-G alleles could not be deter-
mined through the available data in this region. While there were
some differences in minor allele frequency of the variants in table 1
among the three races, there did not seem to be any correlation
with the strength of direction of the associations. Further research
is warranted to validate these findings and to determine the
function of the SNP or if it is in LD with known SNPs in other
studies.
We limited our analysis to clearance of HR-HPV infections
since these types are most likely to be associated with cervical
cancer risk. The underlying hypothesis with this approach is that
the biology and pathogenesis of cancer-causing HR-HPV infec-
tions should be similar in relation to the host. While the model
adjusted for the correlation between the HPV types, it did not
produce hazard ratios specific to each HPV type. We were
underpowered to assess HPV types separately; however the HERS
cohort is one of the largest HIV-positive cohorts with over four
years of HPV follow-up data in the United States. Our sample was
comprised of 400 women (258 African Americans, 87 European
Americans, and 55 Hispanics), which reduced the statistical power
to detect significant findings after adjusting for multiple genetic
testing, especially when analyzing the three races separately.
However, we were able to observe several significant SNPs in the
separate analyses for African Americans and European Ameri-
cans. The ImmunoChip was designed for use in European
populations and could be less informative for other ethnic groups if
the disease-associated variants are not shared between them [23].
The sample sizes for European Americans and Hispanics were
small, so any race specific associations need further evaluations in
larger cohorts. Several SNPs that were significantly associated in
multiple races independently seem interesting, even for smaller
sample size. Few other SNPs have been shown to be significantly
associated with HPV clearance in another cohort of HIV+
adolescents (REACH); however, most were not included in the
ImmunoChip and of the few included (e.g. rs228942 and
rs9292618) [27], they were not significantly associated with HPV
clearance in HERS. REACH comprised of adolescents also at
early period of infection and HERS only had adults, mostly after
several years of infection and thus may indicate different network
of immune-related genes involved in the two scenarios and will
need caution in interpretation requiring further research.
Of note, the Q-Q plot (Figure S1 A–D) had high deviation
(lamda values of 1.23, 1.49, and 1.57 in European Americans,
African Americans and Hispanics, respectively) from the expected
line. Caution is needed to interpret these associations as they might
also be due to population stratification, repeated measures and the
inter-relationships, the Cox proportional hazard model, or the
nature of ImmunoChip SNPs that are in high LD within the fine-
mapped regions, like MHC on chromosome 6 [45,46]. Women
with multiple HPV infections were included in the Cox
proportional hazard model with the WLW extension, which
should account for the correlation between the individuals’ data
being used multiple times, but this could have an effect on the Q-
Q plot due to the population substructure. The ImmunoChip has
dense coverage of the MHC region as well as other regions so this
may explain the deviation. Since the SNPs are close together, they
are in high LD and therefore result in similar p-values. To our
knowledge, the majority of genetic studies model the association
using logistic regression, and the same assumptions of the Q-Q
plot may not hold for the Cox proportional hazard model. The
results could reflect a true association since we are assessing the
association between a virus and immune related genes; therefore,
we would expect a complex network of genes to play a role in
clearance of HR-HPV and our significant findings are biologically
plausible. Such an approach and methods have not been used
often, specifically with high density SNP analyses; thus, it is
difficult to interpret the actual reason of the observed deviations.
This analysis assessing SNPs in immune related genes and their
associations with HR-HPV clearance brought forth hypotheses
regarding several significant SNPs and gene regions. While these
SNPs are associated with HPV clearance, future studies could
examine if they are also associated with progression of pre-cancer
neoplasia in larger cohorts with adequate events during follow-up
periods. The variants in the current ImmunoChip are based on a
consortium of genes involved in autoimmune diseases, and do not
represent the comprehensive genes involved in human immunity.
However, future research is needed to validate these associations
and finemap the gene regions (which are not as dense in
ImmunoChip for most regions) to identify one or multiple rare
variants in LD with the functionally associated SNPs in
ImmunoChip, specifically with MAGI-3, SMAD3 and HLA-G or
other biologically plausible genes, potentially involved with HPV
clearance.
Supporting Information
Figure S1 Quantile-quantile (Q-Q) plot showing the association
P-values of single nucleotide polymorphisms (SNPs) in the
ImmunoChip with the time to clearance of HR-HPV. The X-
axes display the expected 2log10 P-value, the Y-axes display the
observed 2log10 P-value.
(TIF)
Table S1 Results of Cox Proportional Hazard Ratios (HR)
associated with time to clearance of high-risk (HR-HPV) HPV
infection for all the SNPs in the ImmunoChip in the race-adjusted
analysis (Adujsted), individual race-specific analysis (EA=Euro-
pean American, AA=African American, HIS=Hispanic), and
pooled analysis (Meta Analysis) of the three races separately.
(TXT)
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